Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
⁸⁹Zr-Df-IAB22M2C Infusion · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| ⁸⁹Zr-Df-IAB22M2C Infusion | EXPERIMENTAL | 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes |
| Name | Type | Description |
|---|---|---|
| ⁸⁹Zr-Df-IAB22M2C Infusion | DRUG | A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes. |
Inclusion Criteria: 1. Patients with selected solid malignancies (NSCLC, SCLC, SqCCHN, melanoma, merkel cell tumor, renal, bladder, hepatocellular, triple negative breast, or gastroesophageal cancer) or Hodgkin's lymphoma 2. At least 1 measurable lesion documented on CT/MRI (RECIST criteria 1.1) 3....
⁸⁹Zr-Df-IAB22M2C Infusion is an investigational positron-emission tomography (PET) imaging agent being developed by Telix Pharmaceuticals Limited. It is designed for use in oncology imaging, specifically to visualize immune cell activity in patients with selected solid malignancies or Hodgkin lymphoma. It is administered as an infusion and is currently in Phase 1 clinical development.
⁸⁹Zr-Df-IAB22M2C Infusion is being studied for use in positron-emission tomography (PET) imaging in oncology. The Phase 1 trial evaluated it in patients with selected solid malignancies or Hodgkin lymphoma, where it was used with PET/CT imaging to assess immunomodulation. It is an investigational imaging agent and is not approved for commercial use.
⁸⁹Zr-Df-IAB22M2C Infusion is being developed by Telix Pharmaceuticals Limited, which trades under the ticker TLX. Telix is the sponsor of the clinical program for this investigational PET imaging agent.
⁸⁹Zr-Df-IAB22M2C Infusion is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. As a Phase 1 investigational agent, it has not been approved by the FDA for any indication.
⁸⁹Zr-Df-IAB22M2C Infusion has been evaluated in one completed Phase 1 clinical trial, NCT03107663, titled ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma. The trial enrolled 15 participants in the United States and was an uncontrolled, non-randomized study.